{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:16:32Z","timestamp":1790846192264,"version":"4.1.0"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2021,4,13]]},"DOI":"10.18632\/oncotarget.27930","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T20:11:35Z","timestamp":1617826295000},"page":"859-872","source":"Crossref","is-referenced-by-count":10,"title":["High <i>in vitro<\/i> and <i>in vivo<\/i> synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC"],"prefix":"10.18632","volume":"12","author":[{"given":"Elodie","family":"Montaudon","sequence":"first","affiliation":[{"name":"Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"El Botty","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Vacher","sequence":"additional","affiliation":[{"name":"Department of Genetics, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"D\u00e9as","sequence":"additional","affiliation":[{"name":"Xentech, Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Naguez","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Chateau-Joubert","sequence":"additional","affiliation":[{"name":"BioP\u00f4le Alfort, National Veterinary School of Alfort, Maisons Alfort, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Treguer","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmilla","family":"de Plater","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le\u00efla","family":"Zemoura","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Foch, Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"N\u00e9mati","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Nicolas","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Chapelier","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, H\u00f4pital Foch, Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Livartowski","sequence":"additional","affiliation":[{"name":"Institut du Thorax Curie Montsouris, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cairo","sequence":"additional","affiliation":[{"name":"Xentech, Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Daniel","sequence":"additional","affiliation":[{"name":"Institut du Thorax Curie Montsouris, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Brevet","sequence":"additional","affiliation":[{"name":"CYPATH, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Marangoni","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Meseure","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Roman-Roman","sequence":"additional","affiliation":[{"name":"Department of Translational Research, Institut Curie, PSL University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bieche","sequence":"additional","affiliation":[{"name":"Department of Genetics, Institut Curie, Paris, France"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Institut du Thorax Curie Montsouris, Institut Curie, Paris, France"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Decaudin","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France"},{"name":"Department of Medical Oncology, Institut Curie, Paris, France"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma.","volume":"51","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers.","volume":"48","author":"Cancer Genome Atlas Research Network","year":"2012","journal-title":"Nature"},{"key":"3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1634\/theoncologist.2007-0171","article-title":"The potential role of mTOR inhibitors in non-small cell lung cancer.","volume":"1","author":"Rossi","year":"2008","journal-title":"Oncologist"},{"key":"4","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/annonc\/mdp060","article-title":"Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.","volume":"2","author":"Nogova","year":"2009","journal-title":"Ann Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.jtho.2019.05.029","article-title":"SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).","volume":"1","author":"Gandara","year":"2019","journal-title":"J Thorac Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1097\/JTO.0000000000000607","article-title":"Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.","volume":"1","author":"Reck","year":"2015","journal-title":"J Thorac Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000442147","article-title":"A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer.","volume":"6","author":"Govindan","year":"2016","journal-title":"Chemotherapy"},{"key":"8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.21037\/tlcr.2019.04.19","article-title":"A phase I\/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer.","volume":"8","author":"Szabo","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1002\/cncr.25264","article-title":"Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent\/refractory nonsmall cell lung cancer.","volume":"11","author":"Khuri","year":"2010","journal-title":"Cancer"},{"key":"10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/JTO.0b013e318282709c","article-title":"Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.","volume":"8","author":"Fu","year":"2013","journal-title":"J Thorac Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1097\/JTO.0000000000000183","article-title":"A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.","volume":"9","author":"Bowles","year":"2014","journal-title":"J Thorac Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejca.2017.08.027","article-title":"A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.","volume":"8","author":"Dy","year":"2017","journal-title":"Eur J Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/annonc\/mdy245","article-title":"Vistusertib (dual m-TORC1\/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.","volume":"2","author":"Evans","year":"2018","journal-title":"Ann Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/JTO.0b013e3180cc2587","article-title":"Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer.","volume":"2","author":"Leof","year":"2007","journal-title":"J Thorac Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.lungcan.2017.03.009","article-title":"A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and\/or disease progression following prior erlotinib or gefitinib.","volume":"10","author":"Schnell","year":"2017","journal-title":"Lung Cancer"},{"key":"16","doi-asserted-by":"publisher","first-page":"s4628","DOI":"10.1158\/1078-0432.CCR-07-0717","article-title":"Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non-small cell lung cancer.","volume":"1","author":"J\u00e4nne","year":"2007","journal-title":"Clin Cancer Res"},{"key":"17","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1097\/JTO.0b013e3182614835","article-title":"Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.","volume":"7","author":"Johnson","year":"2012","journal-title":"J Thorac Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1634\/theoncologist.2014-0449","article-title":"Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.","volume":"2","author":"Burris","year":"2015","journal-title":"Oncologist"},{"key":"19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/cncr.22816","article-title":"Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.","volume":"11","author":"Miller","year":"2007","journal-title":"Cancer"},{"key":"20","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1097\/JTO.0b013e3181ec1531","article-title":"Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.","volume":"5","author":"Miller","year":"2010","journal-title":"J Thorac Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cllc.2013.11.007","article-title":"A phase I study of temsirolimus and thoracic radiation in non-small-cell lung cancer.","volume":"1","author":"Govindan","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"22","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/annonc\/mdv105","article-title":"Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.","volume":"2","author":"Levy","year":"2015","journal-title":"Ann Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2019.03.015","article-title":"Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.","volume":"11","author":"Ng","year":"2019","journal-title":"Eur J Cancer"},{"key":"24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000348584","article-title":"A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer.","volume":"5","author":"Govindan","year":"2013","journal-title":"Chemotherapy"},{"key":"25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s10637-016-0418-8","article-title":"A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.","volume":"3","author":"Wisinski","year":"2017","journal-title":"Invest New Drugs"},{"key":"26","doi-asserted-by":"publisher","first-page":"21674","DOI":"10.18632\/oncotarget.24670","article-title":"Selumetinib-based therapy in uveal melanoma patient-derived xenografts.","volume":"9","author":"Cassoux","year":"2018","journal-title":"Oncotarget"},{"key":"27","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.","volume":"2","author":"Cai","year":"2015","journal-title":"Nat Med"},{"key":"28","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/clinchem\/45.8.1148","article-title":"Real-time reverse transcription- PCR assay for future management of ERBB2-based clinical applications.","volume":"4","author":"Vidaud","year":"1999","journal-title":"Clin Chem"},{"key":"29","doi-asserted-by":"publisher","first-page":"e82241","DOI":"10.1371\/journal.pone.0082241","article-title":"Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer.","volume":"8","author":"Lanczky","year":"2013","journal-title":"PLoS One"},{"key":"30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.lungcan.2018.02.005","article-title":"Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS\/TP53 mutations in lung adenocarcinoma.","volume":"11","author":"Brevet","year":"2018","journal-title":"Lung Cancer"},{"key":"31","doi-asserted-by":"publisher","first-page":"33542","DOI":"10.18632\/oncotarget.9552","article-title":"Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.","volume":"7","author":"Emery","year":"2016","journal-title":"Oncotarget"},{"key":"32","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations.","volume":"3","author":"Jodrell","year":"2016","journal-title":"Bioinformatics"},{"key":"33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.canlet.2009.03.004","article-title":"PI3K\/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines.","volume":"28","author":"Stanbridge","year":"2009","journal-title":"Cancer Lett"},{"key":"34","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/cam4.991","article-title":"Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression.","volume":"6","author":"Harada","year":"2017","journal-title":"Cancer Med"},{"key":"35","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2147\/dddt.s63235","article-title":"Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells","volume":"8","author":"Yang","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"36","doi-asserted-by":"publisher","first-page":"36666","DOI":"10.18632\/oncotarget.9134","article-title":"Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.","volume":"7","author":"Dormond","year":"2016","journal-title":"Oncotarget"},{"key":"37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12885-019-5503-x","article-title":"Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels.","volume":"1","author":"Vissers","year":"2019","journal-title":"BMC Cancer"},{"key":"38","first-page":"7992","article-title":"Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer.","volume":"6","author":"Harris","year":"2001","journal-title":"Cancer Res"},{"key":"39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1200\/JCO.2003.11.132","article-title":"Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer.","volume":"2","author":"O'Byrne","year":"2003","journal-title":"J Clin Oncol"},{"key":"40","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/sj.bjc.6605690","article-title":"High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.","volume":"10","author":"Hofman","year":"2010","journal-title":"Br J Cancer"},{"key":"41","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.mct-15-0897","article-title":"Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.","volume":"1","author":"Ahmad","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"42","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/annonc\/mdv354","article-title":"A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.","volume":"2","author":"De Pas","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T15:24:04Z","timestamp":1618327444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4,13]]}},"alternative-id":["27930"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27930","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]}}}